The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
May 14th 2024
The artificial intelligence (AI)-powered module provides a prostate segmentation tool for MRI-guided transurethral ultrasound ablation (TULSA) procedures in patients with prostate cancer.
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
May 21, 2024
Register Now!
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Radiotherapy for Prostate Cancer: Study Says MRI Guidance Significantly Reduces GU and GI Toxicities
October 28th 2022For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Transvaginal Ultrasound or MRI: Which is More Effective in Evaluating Endometrial Cancer?
October 26th 2022In a new study looking at pre-operative assessment of low-grade endometrial cancer, researchers found that while magnetic resonance imaging (MRI) had 20 percent higher specificity than transvaginal ultrasound for deep myometrial invasion, there was no difference in sensitivity.
Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer
October 24th 2022Five weeks of radiation therapy is just as effective as eight weeks of radiation treatment for men with high-risk prostate cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Philips Gets FDA Nod for MRI Head and Neck Radiotherapy Application
October 20th 2022For physicians performing radiotherapy treatment of soft tissue tumors in the head and neck, the MRCAT Head and Neck offers an artificial intelligence (AI) application that allows the use of magnetic resonance imaging (MRI) as the primary or sole imaging for procedure planning.
Recognizing the Role of Enterprise Imaging in Handling and Protecting Sensitive Patient Information
October 19th 2022While facilitating interdisciplinary colloaboration is a central objective with enterprise imaging platforms, this author says implementation of these platforms must ensure optimal patient privacy in sensitive cases involving abuse, assault and domestic violence.
Could Brain MRI Screening be Beneficial for Patients with Inflammatory Breast Cancer?
October 11th 2022While current consensus guidelines do not recommend the use of brain MRI screening in patients with breast cancer, a new study shows significantly elevated risks for the development of central nervous system metastasis in patients with inflammatory breast cancer.
Adjunctive AI Software for Brain MRI Gets FDA Clearance for Assessing High-Grade Gliomas
October 10th 2022Incorporating artificial intelligence (AI)-based technology, Neosoma HGG reportedly demonstrated a 95.5 percent accuracy rate in measuring brain tumor volume on brain magnetic resonance imaging (MRI) scans at various points during the treatment of patients with high-grade gliomas.
Digital Breast Tomosynthesis and Breast Density: What a New Study Reveals
October 6th 2022In a large study of nearly 100,000 women, researchers found that the combination of digital breast tomosynthesis (DBT) and synthesized mammography had more than triple the detection rate for invasive breast cancer in extremely dense breasts in comparison to digital mammography alone.
Study Finds No Benefit to MRI Screening in Women with High-Risk Breast Lesions
October 3rd 2022In a study involving nearly 700 patients with atypical ductal or lobular hyperplasia, or lobular carcinoma in situ, researchers found no difference in four-year breast cancer detection rates between women who had screening mammography and breast magnetic resonance imaging (MRI), and women who only had mammography screening.
Prospective MRI Study Reveals Impact of Opioid Exposure on the Fetal Brain
September 30th 2022Researchers found that in utero opioid exposure resulted in seven out of 14 2D biometric measurements of the fetal brain being smaller on magnetic resonance imaging (MRI) scans in comparison to fetuses without opioid exposure.
MRI Deep Learning Software from GE Healthcare Gets Expanded FDA Clearance
September 29th 2022AIR Recon DL, a deep learning-based image reconstruction software, will now be available with 3D sequences as well as PROPELLER motion-insensitive sequences on magnetic resonance imaging (MRI) scanners from GE Healthcare.
A Closer Look at Ultrasound and MRI Alternatives for Head and Neck Imaging
September 29th 2022In light of recent shortages of iodinated contrast media, researchers from Australia suggest in a new publication that ultrasound and magnetic resonance imaging (MRI) can be viable first-line imaging options for a number of non-urgent presentations of the head and neck.
What a New Meta-Analysis Reveals About Breast Density, Mammography and MRI Screening
September 28th 2022Assessing data from 386,590 women, researchers noted that women with extremely dense breast tissue have more than double the risk for breast cancer in comparison to women with average breast density and nearly four times the risk of women with extremely fatty breast tissue.
FDA Approves New MRI Contrast Agent Gadopiclenol
September 22nd 2022Requiring only half of the gadolinium dose of current non-specific gadolinium-based contrast agents (GBCAs), gadopiclenol can be utilized with magnetic resonance imaging (MRI) to help detect lesions with abnormal vascularity in the central nervous system and other areas of the body.
Study Shows Adjunctive Benefit of Pre-Biopsy MRI for Diagnosing Prostate Cancer
September 20th 2022Emerging research suggests that combining pre-biopsy magnetic resonance imaging (MRI) with prostate-specific antigen (PSA) testing more than triples the specificity rate for detecting clinically significant prostate cancer in comparison to sole reliance on a PSA level greater than or equal to 4 ng/mL.
Post-Vaccine Axillary Lymphadenopathy: What a New Chest MRI Study Reveals
September 19th 2022In a new study looking at the development of axillary lymphadenopathy after a second dose of COVID-19 vaccination, researchers found that those who had the Moderna COVID-19 vaccine were 21 percent more likely to have the post-vaccine side effect in comparison to those who had the Pfizer-BioNtech COVID-19 vaccine.